CURABLE provide customization services from research to non-clinical and clinical trial samples at cGMP-certified facilities. In addition to consignment production, CURABLE will expand business to consignment production that provides drug development and manufacturing services at once, and CURABLE will work with customers who need mass production of small molecule new drugs and medicines as well as RNA.
Curable
Category:
Ingredient
Main Business Area
CURABLE developed DDS technology using new microfluidic-based lipid nanoparticles (LNPs) to become a reliable partner for biopharmaceutical developers, and is set to launch in the fourth quarter of 2022 primarily by preparing RNA treatment and vaccine consignment production services.
| Contact Details | 10F, 93 Dongtan-daero 23-gil, Hwaseong-si, Gyeonggi-do +82-31-376-1671info@curablent.com |
|---|
